Cambrex Corporation (CBM)
(Delayed Data from NYSE)
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Genesis Healthcare (GEN) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Genesis Healthcare's (GEN) third-quarter results are likely to reflect weak revenues, partially offset by same store facility growth and lower expenses.
ALXN or CBM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
ALXN or CBM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
ALXN vs. CBM: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Earnings Preview: Cambrex (CBM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CBM or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBM vs. TECH: Which Stock Is the Better Value Option?
CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBM vs. ALKS: Which Stock Is the Better Value Option?
CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBM vs. ALKS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
by Swarup Gupta
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
CBM vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
CBM vs. TECH: Which Stock Is the Better Value Option?
Can Cambrex (CBM) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Cambrex (CBM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cambrex (CBM) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Cambrex (CBM) delivered earnings and revenue surprises of 17.65% and -0.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Cambrex (CBM) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Pick Cambrex Corporation (CBM) Stock?
by Zacks Equity Research
Is Cambrex Corporation (CBM) a great pick from the value investor's perspective right now? Read on to know more.
Cambrex (CBM) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Cambrex (CBM) delivered earnings and revenue surprises of 2.86% and -15.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Cambrex (CBM) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cambrex (CBM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CBM or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBM vs. ILMN: Which Stock Is the Better Value Option?
Is Cambrex (CBM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CBM or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBM vs. ALKS: Which Stock Is the Better Value Option?
Cambrex (CBM) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cambrex (CBM) delivered earnings and revenue surprises of -16.95% and -18.16%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cambrex (CBM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.